Fate Therapeutics (FATE) EBITDA Margin Growth (5y) (2017 - 2026)
Fate Therapeutics (FATE) EBITDA Margin Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Fate Therapeutics | 292.87 Mn | 292.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,568.00 |
| Dec 31, 2025 | -232,612.00 |
| Sep 30, 2025 | -157,851.00 |
| Jun 30, 2025 | -141,325.00 |
| Mar 31, 2025 | -116,262.00 |
| Dec 31, 2024 | -228,203.00 |
| Sep 30, 2024 | -58,740.00 |
| Jun 30, 2024 | 18,923.00 |
| Mar 31, 2024 | -187,606.00 |
| Dec 31, 2023 | -186,055.00 |
| Sep 30, 2023 | -101,091.00 |
| Jun 30, 2023 | -479,683.00 |
| Mar 31, 2023 | 132,131.00 |
| Dec 31, 2022 | 104,698.00 |
| Sep 30, 2022 | 43,113.00 |
| Jun 30, 2022 | 48,470.00 |
| Mar 31, 2022 | 56,648.00 |
| Dec 31, 2021 | 33,880.00 |
| Sep 30, 2021 | 43,365.00 |
| Jun 30, 2021 | 43,057.00 |